Skip to main content
MedNext FormularyMedNext
Back to Blog
Clinical Guides5 min read|

Sertraline: First-Line SSRI for Depression and Anxiety

Sertraline is one of the most widely prescribed SSRIs. A practical guide to initiation, titration, and managing discontinuation.

Reviewed by MedNext Clinical Team

Sertraline is among the most widely prescribed antidepressants globally and consistently ranks as a first-line choice for major depressive disorder (MDD), generalised anxiety disorder (GAD), panic disorder, social anxiety disorder, and post-traumatic stress disorder (PTSD). A large network meta-analysis found sertraline to have one of the most favourable efficacy-to-tolerability profiles among commonly used antidepressants, making it a practical starting point for most patients [1].

Mechanism of Action

Sertraline is a selective serotonin reuptake inhibitor (SSRI). It blocks the serotonin transporter (SERT), increasing synaptic serotonin availability. Unlike some SSRIs, sertraline has minimal affinity for histaminergic, muscarinic, or adrenergic receptors, contributing to its relatively clean side-effect profile.

Initiation and Titration

Treatment is typically started at 50 mg once daily. In anxious or sensitive patients, beginning at 25 mg for the first week can improve early tolerability. The dose can be increased in 25–50 mg increments at intervals of no less than one week, up to a maximum of 200 mg daily.

Patients and clinicians should be aware that the therapeutic effect on mood typically takes 2–4 weeks to emerge, while some side effects (nausea, initial anxiety, insomnia) may appear earlier. Clear counselling at initiation reduces premature discontinuation.

Common Side Effects

  • GI effects: Nausea is most common in the first 1–2 weeks and usually resolves. Taking sertraline with food can help.
  • Sexual dysfunction: Reduced libido, delayed ejaculation, and anorgasmia affect a significant proportion of patients and are often underreported.
  • Insomnia or sedation: Variable — adjust timing of dose accordingly (morning for insomnia, evening for sedation).
  • Increased anxiety: An initial paradoxical increase in anxiety can occur, particularly in panic disorder. Starting low and slow mitigates this risk.

Discontinuation Syndrome

Abrupt cessation or rapid tapering of sertraline can cause discontinuation syndrome: dizziness, electric shock sensations ("brain zaps"), flu-like symptoms, irritability, and insomnia. This is not dependence or addiction, but reflects neuroadaptation. When stopping treatment, taper the dose gradually over several weeks to months, particularly after prolonged use or at higher doses.

Serotonin Syndrome

Serotonin syndrome is a potentially life-threatening condition resulting from excess serotonergic activity. Warning signs include the clinical triad of neuromuscular abnormalities (tremor, clonus, hyperreflexia), autonomic instability (hyperthermia, tachycardia, diaphoresis), and altered mental status (agitation, confusion). Risk is highest when sertraline is combined with other serotonergic agents — MAOIs (absolutely contraindicated), tramadol, triptans, linezolid, or St John’s Wort. Patients should be counselled to report these symptoms promptly.

Duration of Treatment

For a first episode of MDD, continue treatment for at least 6–12 months after remission to reduce relapse risk. For recurrent depression (two or more episodes), longer-term maintenance therapy should be considered and discussed with the patient [1].

References

  1. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357-1366.

Ready to try MedNext Formulary?

Access 2,866 drugs, AI-powered search, and real-time interaction checking. Start your free 7-day trial today.